News | January 28, 2025
Laurus Labs posts Q3 FY25 consolidated PAT higher at Rs. 92.30 Cr
Laurus Labs has reported total income of Rs. 1,424.47 crores during the period ended December 31, 2024
Laurus Labs has reported total income of Rs. 1,424.47 crores during the period ended December 31, 2024
700 new scientific and high-skilled jobs to be created in Greater Toronto Area, investing to execute more than 210 AstraZeneca global clinical studies
The launch of Chlorpromazine Hydrochloride for Injection is the latest in a series of recent product launches from Piramal Critical Care
The revenue from operations in Q3 FY25 is Rs. 8,358.6 crore, up 16% YoY
The project will provide additional support for late-stage development and licensure of pre-pandemic mRNA-based vaccines
In 2023, Endox had revenues of approximately SEK 65 million
According to IQVIA, the European market for Buprenorphine-based opioid dependency treatments in 2023 surpassed USD 355 million annually
Acquisition expands high-value medical platform
Successfully transformed the organization from a two-country operation focused on development and manufacturing to a fully integrated company with a strong commercial engine bringing us closer to patients in over 120 countries
Menkes disease is a rare X-linked recessive pediatric disease caused by gene mutations of the copper transporter ATP7A
Subscribe To Our Newsletter & Stay Updated
